Histone deacetylase inhibitors for the treatment of myelodysplastic syndrome and acute myeloid leukemia.
about
Histone deacetylase inhibition in the treatment of acute myeloid leukemia: the effects of valproic acid on leukemic cells, and the clinical and experimental evidence for combining valproic acid with other antileukemic agentsClinical use and applications of histone deacetylase inhibitors in multiple myelomaEpigenomics of leukemia: from mechanisms to therapeutic applicationsNuclear receptor coregulators: modulators of pathology and therapeutic targetsChildhood acute myeloid leukaemiaEpigenetic disregulation in oral cancerTelomerase Activation in Hematological MalignanciesPanobinostat enhances cytarabine and daunorubicin sensitivities in AML cells through suppressing the expression of BRCA1, CHK1, and Rad51Synergistic re-activation of epigenetically silenced genes by combinatorial inhibition of DNMTs and LSD1 in cancer cellsEffects of valproic acid and pioglitazone on cell cycle progression and proliferation of T-cell acute lymphoblastic leukemia Jurkat cellsHistone deacetylase inhibitor pracinostat in doublet therapy: a unique strategy to improve therapeutic efficacy and to tackle herculean cancer chemoresistance.Epigenetic therapies in MDS and AMLHistone deacetylase inhibitor (HDACI) mechanisms of action: emerging insights.Histone deacetylase 3 as a novel therapeutic target in multiple myeloma.New insights into the treatment of multiple myeloma with histone deacetylase inhibitors.The oral HDAC inhibitor pracinostat (SB939) is efficacious and synergistic with the JAK2 inhibitor pacritinib (SB1518) in preclinical models of AML.Small molecule inhibitors in acute myeloid leukemia: from the bench to the clinicOverexpression of GATA1 confers resistance to chemotherapy in acute megakaryocytic Leukemia.Inhibition of histone methyltransferase EZH2 depletes leukemia stem cell of mixed lineage leukemia fusion leukemia through upregulation of p16.Rational Combinations of Targeted Agents in AMLSIRT1 deacetylase promotes acquisition of genetic mutations for drug resistance in CML cells.Epigenetic alterations in bladder cancer and their potential clinical implications.Selective Inhibitors of Histone Deacetylases 1 and 2 Synergize with Azacitidine in Acute Myeloid Leukemia.Digging deep into "dirty" drugs - modulation of the methylation machinery.Synergistic anti-leukemic interactions between panobinostat and MK-1775 in acute myeloid leukemia ex vivo.The combination of valproic acid, all-trans retinoic acid and low-dose cytarabine as disease-stabilizing treatment in acute myeloid leukemiaEpigenetic regulation of the human telomerase reverse transciptase gene: A potential therapeutic target for the treatment of leukemia (Review).Cellular determinants for preclinical activity of a novel CD33/CD3 bispecific T-cell engager (BiTE) antibody, AMG 330, against human AML.Histone deacetylase inhibitors induce apoptosis in myeloid leukemia by suppressing autophagyEpigenetic therapy is associated with similar survival compared with intensive chemotherapy in older patients with newly diagnosed acute myeloid leukemiaHistone deacetylases 1 and 2 cooperate in regulating BRCA1, CHK1, and RAD51 expression in acute myeloid leukemia cells.Implication of microRNAs in the pathogenesis of MDS.Epigenetics and blood disorders.SIAH proteins: critical roles in leukemogenesis.The role of chromatin modifiers in normal and malignant hematopoiesisAlterations of DNA methylome in human bladder cancer.Differentiation therapy of acute myeloid leukemia.Molecular and Epigenetic Mechanisms of MLL in Human Leukemogenesis.Epigenetic alterations in acute myeloid leukemias.Understanding chronic neutropenia: life is short.
P2860
Q24633763-FB70732B-B56A-4855-85E4-C926FA695869Q26745930-27E10BD9-8F81-4AD7-BF58-80F75E072470Q26823403-AA2C7271-B092-4550-BBB8-970079EB1E27Q26859163-9F5AF21A-A2CF-4294-997B-09AF7C7B9B74Q27005960-8E70D478-28DE-476C-B5C5-15F59403D536Q27007004-0B5B540D-B15C-470F-9DD6-19015068A833Q28068238-63AB8FE2-AAFF-4451-A9E0-BA7F1684E386Q28535006-30CABA86-EC11-4A4D-A9EC-C0A1994C6201Q28536924-77D42B00-0196-4C87-AC6E-9DE293E77316Q28831371-09AB7C30-1266-47AC-8D5B-493474314CB3Q30251920-A4281AAF-A514-484D-8E99-0142C953AC11Q33863567-D148C67E-4938-42F3-A306-D0320AFC1910Q33983255-4BE6D89A-FC4C-4051-99D2-9E9CE9C27CB8Q34194704-CD49A851-3A02-4D7B-9058-3155127792A2Q34224278-E1C97EF2-F737-4A0E-BE10-BD4C55C60026Q34640790-1833BB63-55C7-48E3-A94E-C2854F1754CEQ34817365-F096C976-1A0B-49D4-90F5-2DDECB44A979Q34849602-42AE492D-AD48-4CF9-B197-540AB90CBFAEQ35051547-FB2F4039-2D0C-45D3-9B8E-E260C1A32432Q35750491-48293906-4CCC-45CE-B2AD-BFD36C3D5C79Q36035627-6A35F84A-FA43-4934-A6B0-3688C99D39F9Q36095721-8E95578F-5E56-47AD-916A-4F7D2D02DB42Q36242646-CA395460-9A62-4689-B94A-FF5207F7E31FQ36523796-4690785D-09ED-476C-ABDB-FFC16B0D5D49Q36843733-FE6EDAF3-C4AE-46E2-AA21-BCD65CF61923Q37153361-6A8E31D5-2E31-497A-B488-3C2CD64B347EQ37211663-95CEDAC7-FE27-4E91-A0EB-24C0FB1710FEQ37512086-821A1297-200D-4846-AD9E-045E5AD50FB7Q37626910-E452DF8C-F15F-4115-B1A4-90E6683BF7FDQ37635209-FBF6DC72-45FD-4EB2-BA90-AFAE5A79769FQ37701599-5CC63B8D-BF1A-4936-BCD4-17C85E401F63Q38008748-213FE2E7-8E9E-4336-B595-3AF718ABC595Q38019955-E37DE8D7-4751-46D8-854B-1B156CDDA267Q38049544-424EC187-5249-412F-8945-DCDE284E1319Q38071526-DA29CDAC-F5BE-45AA-88FC-2CBF938EEE59Q38131409-4B75D814-2DF3-4F46-9869-28195F7D5492Q38161360-B0B3E60A-380D-450F-9CB9-47D6963C8357Q38161393-4F930827-8173-4706-A6C1-CF2ABA6CCC58Q38264968-AA6E2585-CD3A-4CFD-BDCF-CC1D07D464B2Q38604646-DEB9068F-176D-4F0F-AFCF-4E13584D069A
P2860
Histone deacetylase inhibitors for the treatment of myelodysplastic syndrome and acute myeloid leukemia.
description
2010 nî lūn-bûn
@nan
2010年の論文
@ja
2010年学术文章
@wuu
2010年学术文章
@zh-cn
2010年学术文章
@zh-hans
2010年学术文章
@zh-my
2010年学术文章
@zh-sg
2010年學術文章
@yue
2010年學術文章
@zh
2010年學術文章
@zh-hant
name
Histone deacetylase inhibitors ...... me and acute myeloid leukemia.
@en
Histone deacetylase inhibitors ...... me and acute myeloid leukemia.
@nl
type
label
Histone deacetylase inhibitors ...... me and acute myeloid leukemia.
@en
Histone deacetylase inhibitors ...... me and acute myeloid leukemia.
@nl
prefLabel
Histone deacetylase inhibitors ...... me and acute myeloid leukemia.
@en
Histone deacetylase inhibitors ...... me and acute myeloid leukemia.
@nl
P2093
P2860
P356
P1433
P1476
Histone deacetylase inhibitors ...... me and acute myeloid leukemia.
@en
P2093
A Quintás-Cardama
F P S Santos
G Garcia-Manero
P2860
P2888
P304
P356
10.1038/LEU.2010.276
P577
2010-11-30T00:00:00Z